Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

Blood clot risk means additional monitoring needed with patients taking ponatinib

By News team

Healthcare professionals should apply more caution to the use of ponatinib (Iclusig) and carry out additional monitoring of patients receiving the anticancer drug, due to an increased risk of blood clots.

The recommendations have been made by the European Medicines Agency’s Pharmacovigilance Risk Assessment Committee following new information suggesting that the frequency of vascular occlusion events is higher than was observed when the medicine was approved in the EU in July 2013. The committee has also recommended that an in-depth review be carried out of the medicine’s benefit-risk ratio.

Moves to update product information were started on 24 October 2013 and the advice of the PRAC will now be considered by the Committee for Medicinal Products for Human Use (CHMP). An opinion is expected from the CHMP between 18 and 21 November.

See also: Ponatinib launched for chronic myeloid and acute lymphoblastic leukaemias

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2013.11130250

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Supplementary images

  • Iclusig (ponatinib)

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.